Oncologist Urge FDA to Allow Cancer Patients Access to Silicone Implants, But Continue Study
In Brief: Healy to Name Jay Moskowitz Deputy Direct, Promote Mahoney To Deputy Budge Director
NCI To File Record No. Of INDS In ’92, Expand Phase 1 Trials
Advisors Ok New RFP For Natural Product Large-Scale Production
National Coalition Dinner Honors Cancer Program Founders, Advocates, And Cancer Survivors
DES Exposure Studies Below Payline; NCI Considers Contracts
ICCCR Issues RFP For Cancer Risk Scale
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
